# Persistent Inadequate Disease Control and Therapeutic Inertia in Moderate-to-Severe Atopic Dermatitis: A 12-month Longitudinal Analysis of Real-world Outcomes from the TARGET-DERM AD registry

## Lawrence F. Eichenfield MD<sup>1,2</sup>, Ayman Grada MD<sup>3</sup>, Keith D. Knapp PhD<sup>4</sup>, Breda Munoz PhD<sup>4</sup>, Jonathan I. Silverberg MD PhD MPH<sup>5</sup> on behalf of the TARGET-DERM AD Investigators

<sup>1</sup>Departments of Dermatology and Pediatrics, University of California San Diego, La Jolla, CA, USA; <sup>3</sup>AbbVie Inc. North Chicago, Illinois, USA; <sup>4</sup>Target RWE. Durham, North Carolina, USA; <sup>5</sup>George Washington University School of Medicine and Health Sciences. Washington D.C., USA.

### Introduction

- Therapeutic inertia is the delay or reluctance in modifying treatment despite treatment goals not being met.
- According to the AHEAD treat-to-target recommendation1, if the agreed treatment targets are not achieved within 3 to 6 months, the treatment response is considered inadequate, and a modification of therapy should be considered.
- Therapeutic inertia is a significant challenge in managing atopic dermatitis (AD) and can lead to suboptimal control of the disease, affecting patient outcomes.
- The extent of therapeutic inertia in AD patients receiving systemic treatment in real-world clinical practice may be underestimated.

#### **Objective**

• To evaluate the occurrence of therapeutic inertia (assessed as non-escalation of therapy despite inadequate disease control) and the proportion of patients with moderate-to-severe AD who continue to show an inadequate response after receiving systemic therapies for a duration of 3 to 12 months.

#### **Methods**

- We evaluated both clinician- and patient-reported outcomes to determine the proportion of patients who did not meet moderate or optimal treatment targets, as defined by the AHEAD guidelines (Table 1).
- AD patients treated with their first advanced systemic therapy (AST), including abrocitinib, dupilumab, tralokinumab, and upadacitinib, or conventional systemic therapy (CST) including methotrexate, cyclosporine, mycophenolate mofetil, azathioprine, systemic corticosteroids, and phototherapy were identified
- Inclusion Criteria
  - Enrolled in TARGET-DERM AD, an observational, longitudinal study of participants with AD across 39 academic and community centers in the United States and Canada
  - All ages included

**Figure 1. Study Schematic** 

- Patient treated with first systemic therapy either advanced or conventional
- Patient had a validated Investigators Global Assessment of AD (vIGA-AD) score of 3 or 4 within 45 days prior to systemic initiation or up to 14 days after
- Patient had at least one vIGA-AD assessment 3-12 months after systemic therapy initiation
- Exclusion criteria
  - Patient had received advanced or conventional systemic AD therapy prior to index date

#### Month 9 Month 3 Enrollment ±45 days ±45 days Month 12 Month 6 1°Systemic ±45 days ±45 days AS CST - 45 days + 14 days AST= Advanced System Therapeutic CST = Conventional Systemic Therapeutic vIGA>=3

#### Table 1. Outcome Targets

Outcome	Moderate Target	Optimal Target
Skin Clearance	IGA ≤2 and 50% BSA improvement	IGA 0/1 and BSA ≤2%
Itch relief	WI-NRS ≥4-point improvement (reduction	WI-NRS 0/1

- Assessments
  - The Investigators Global Assessment of AD (IGA, range 0–4)
  - Body surface area (BSA, range 0-100%) affected by AD
  - Patient-Reported Outcome Measurement Information System (PROMIS) Itch-Severity question evaluating Worst-Itch, (range 0–10)

#### Analyses

- Patient characteristics were summarized using descriptive statistics
- The frequency and proportion of patients not achieving moderate or optimal outcome targets at 3, 6, 9, and 12 months following systemic initiation
- The Kruskal-Wallis and Wilcoxon statistical tests compared the subgroups

#### Results

Table 2. Patient Characteristics at Enrollment

sessme

N=395

Patient characteristic	(N=445)	Patient characteristic	TARGET-	DEF	
Age (years) at		IGA		N=34	57
enrollment	30.8 (21.2)	Mean (SD)	3.3 (0.5)	•	
Mean (SD)	24.0 (445)	Median (n)	3.0 (445)	Moderate – To-S	
Median (n)	0 - 86		,	AD	
Min – Max		BSA		N=21	07
Sex, n (%)		Mean (SD)	26.1 (22.8)		
Female	276 (62.0%)	Median (n)	18.0 (445)	Initiated 1 <sup>st</sup> Sys	
Male	169 (38.0%)	BSA Category, n (%)		enrollm	
Race-Ethnicity, n (%)		Mild, >0% to <16%	212 (47.6%)	N=66	52
Hispanic/Latino	88 (19.8%)	Moderate, 16% - 40%	148 (33.3%)		
NH White	202 (45.4%)	Severe, >40%	85 (19.1%)	Initiated AST	
NH Black	55 (12.4%)	Worst-Itch		N=492	
NH Asian	63 (14.2%)	Mean (SD)	76(22)		
NH Other	19 (4.3%)		7.6 (2.3)	Has at least 1	
Missing	18 (4.0%)	Median (n)	8.0 (243)	follow-up	
		vestigator's Global Assessment of Atopic Derma	titie:		

SD=standard deviation; NH=Non-Hispanic; vIGA-AD validated Investigator's Global Assessment of Atopic Dermatitis BSA=Body Surface Area


#### Table 3. Medication Utilization at Initiation


Medications	3 months (N=419)	6 months (N=394)	9 months (N=371)	12 months (N=342)
Any Conventional Systemic Therapy (CST), n (%)	35 (8.4%)	31 (7.9%)	29 (7.8%)	26 (7.6%)
Cyclosporine	10 (2.4%)	8 (2%)	8 (2.2%)	7 (2%)
Methotrexate	13 (3.1%)	12 (3%)	11 (3%)	10 (2.9%)
Mycophenolate mofetil	2 (0.5%)	2 (0.5%)	1 (0.3%)	1 (0.3%)
Prednisolone	2 (0.5%)	2 (0.5%)	2 (0.5%)	2 (0.6%)
Prednisone, unspecified	8 (1.9%)	7 (1.8%)	7 (1.9%)	6 (1.8%)
Any Advanced Systemic Therapy (AST), n (%)	384 (91.6%)	363 (92.1%)	342 (92.2%)	316 (92.4%)
Abrocitinib	3 (0.7%)	3 (0.8%)	3 (0.8%)	3 (0.9%)
Dupilumab	344 (82.1%)	327 (83%)	312 (84.1%)	296 (86.5%)
Tralokinumab	24 (5.7%)	20 (5.1%)	17 (4.6%)	11 (3.2%)
Upadacitinib	13 (3.1%)	13 (3.3%)	10 (2.7%)	6 (1.8%)

• Dupilumab was the most commonly used AST, with its use exceeding 82% throughout the 12-month follow-up period.

• 36.7% of patients treated with AST were also using concomitant topical corticosteroids or topical calcineurin inhibitors.


#### Figure 3. Therapeutic inertia among AST-treated Patients. Percentages of patients not achieving moderate and optimal treatment targets for skin clearance (IGA X BSA) and itch (WI-NRS)





#### Fall Clinical Conference • Las Vegas, NV • October 24-27, 2024





follow-up assessmen N=50

12 months (N=342)
26 (7.6%)
7 (2%)
10(2.00/)

#### Table 4. Proportion of Patients Not Achieving Moderate Treatment Target by Systemic Treatment Subgroup

<b>A</b> 1		3 Months			6 Months	5		9 Months	
Outcome Measure	AST	CST	Overall	AST	CST	Overall	AST	CST	Overall
GA and BSA									
n/N	78/196	13/22	91/218	44/118	8/15	52/133	35/107	12/19	47/126
%	39.8%	<b>59.1%</b>	41.7%	37.3%	53.3%	39.1%	32.7%	63.2%*	37.3%
WI-NRS									
n/N	139/180	22/24	161/204	133/199	20/15	148/219	67/93	7/11	74/104
%	77.2%	91.7%	78.9%	66.8%	75.0%	67.6%	72.0%	63.6%	71.2%

P<0.05: \*\*P<0.01: n/N=num

- At 6 months, 37% and ~ 67% of AST-treated patients had inadequate responses in terms of skin clearance and itch outcomes, respectively.
- At 12 months, these figures were approximately 30% and 66%, respectively.
- CST-treated patients showed a similar trend.

#### Table 5. Proportion of Patients Not Achieving Optimal Treatment Target by Systemic Treatment Subgroup

0		3 Months	6		6 Months	i		9 Months	
Outcome Metric	AST	CST	Overall	AST	CST	Overall	AST	CST	Overall
IGA and BSA									
n/N	160/196	20/22	180/218	97/118	13/15	110/133	90/107	18/19	108/126
%	81.6%	90.9%	82.6%	82.2%	86.7%	82.7%	84.1%	94.7%	85.7%
Worst Itch									
n/N	159/180	19/24	178/204	158/199	18/20	176/219	91/115	12/14	103/129
%	88.3%	79.2%	87.3%	79.4%	90.0%	80.4%	<b>79.1%</b>	85.7%	79.8%
n/N-numerator/den/	ominator								

n/N=numerator/denominator

- At 6 months, 82% and 79% of AST-treated patients did not meet optimal treatment targets in terms of skin clearance and itch outcomes, respectively.
- At 12 months, these figures were approximately 85% and 88%, respectively.
- CST-treated patients showed a similar trend.

#### **Sensitivity Analysis**

• For the subgroup of 198 patients who began advanced systemic therapy (AST) on or after September 1st, 2021, when additional AST options were approved and available in the market, the results were consistent with the overall cohort. This confirms that therapeutic inertia persists, even with the introduction of newer advanced systemic therapies.

#### Conclusion

- The study reveals that a significant portion of moderate-to-severe AD patients fail to achieve adequate disease control with systemic therapies over 12 months, indicating a substantial presence of therapeutic inertia.
- These findings underscore the importance of adopting a treat-to-target approach, where therapy is adjusted or switched when adequate control is not achieved.


#### Reference


1. Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, Rademaker M, Fomina D, Gutermuth J, Ahn J, Valenzuela F. Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. 2024 Jul 11.

Acknowledgements and Disclosures: Target RWE communities are collaborations among academic & community investigators, the pharmaceutical industry, and patient community advocates. Target RWE communities are sponsored by TARGET PharmaSolutions Inc (d.b.a., Target RWE). The authors would like to thank all the investigators, participants, and research staff associated with TARGET-DERM. ClinicalTrials.gov Identifier: NCT03661866.

LEF Received honoraria as a consultant, speaker and/or advisory board member for Abbvie, Amgen, Arcutis, Aslan, Dermavant, Dermira, Eli Lilly, Galderma, Incyte, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme; investigator (grants to institution) from Abbvie Amgen, Arcutis, Dermavant, Eli Lilly, Galderma, Pfizer, Regeneron, Sanofi-Genzyme; AG is an employee of AbbVie Inc. KK an employee of Target RWE and holds stock options; BM an employee of Target RWE may hold stock options; JC is an employee of Target RWE and may hold stock options; JIS received honoraria as a consultant and/or advisory board member for Abbvie, Afyx, Aobiome, Arena, Asana, BioMX, Bluefin, Bodewell, Boehringer-Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, hithKline, Incyte, Kiniksa, Leo Pharma, Luna, Menlo, Novartis, Pfizer, RAPT, Regeneron, Sanofi-Genzyme: speaker for Abbyle, Eli Lilly, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme: institution received grants from Galderma, Pfizer, Regeneron, Sanofi-Genzyme: speaker for Abbyle, Eli Lilly, Leo Pharma, Pfizer, Regeneron, S







77/91	12/13	89/104
<b>84.6%</b>	<b>92.3%</b>	<b>85.6%</b>
159/180	19/24	178/204
<b>88.3%</b>	<b>79.2%</b>	<b>87.3%</b>